PleoPharma Announces Positive Outcomes from Cannabis Withdrawal Study
PleoPharma, Inc., a company dedicated to addressing cannabis-related health challenges, has shared encouraging results from its CAN-001 Phase 1b clinical trial, which focuses on cannabis withdrawal syndrome (CWS). This study primarily evaluated the pharmacokinetics and pharmacodynamics of their investigational product, PP-01, which combines nabilone and gabapentin to alleviate the withdrawal symptoms associated with cannabis use disorder (CUD).
Study Highlights and Results
At the annual American Academy of Addiction Psychiatry meeting, the company presented its proof-of-concept results indicating how PP-01 can help those experiencing symptomatic distress due to CWS. The clinical trial involved patients diagnosed with moderate to severe CUD and aimed to showcase the therapeutic potential of PP-01.
Participant Insights and Trial Design
Participants reported a daily cannabis use averaging 3.5 grams, while the age of initial use varied between 6 and 22 years, with a median age of 14. By using DSM-5 criteria, the trial identified that 64% of participants had severe CUD and the remaining 36% had moderate CUD.
Significant Findings
The results were remarkable: daily administration of PP-01 showed a significant reduction in CWS ratings, starting just four hours after the first dose and maintaining this effectiveness throughout the five-day assessment period. Of note, participants reported a decrease in cravings and improved quality of sleep, along with a reduction in the discomfort caused by withdrawal symptoms when compared to placebo. Side effects were minimal, with no serious adverse incidents reported.
The Growing Need for Treatment Options
As cannabis use rises, so too does the prevalence of CUD in the United States. Recent data indicated that around 19.2 million Americans struggle with this disorder, yet only 1.64 million receive treatment. The statistics underscore the urgent need for effective interventions as trends suggest an annual increase in treatment seekers. Currently, no medications have FDA approval for managing CWS or CUD, amplifying the importance of PleoPharma's work with PP-01.
PleoPharma's Commitment to Innovation
PleoPharma, Inc. not only focuses on the clinical development of PP-01 but also aims to pioneer a new category of FDA-approved treatment that specifically tackles cannabis withdrawal symptoms. Employeeed by a team with a rich history of clinical successes, PleoPharma is keenly aware of the stakes involved in mental health and addiction through their therapeutic developments.
Expert Team and Future Ventures
The management and board at PleoPharma have substantial experience, having overseen more than 50 product approvals worldwide, as well as 100+ Investigational New Drug applications. Their vision is clear: to advance research and ultimately improve patient care through innovative solutions in cannabis health.
Frequently Asked Questions
What is PleoPharma, Inc. known for?
PleoPharma, Inc. specializes in developing treatments for cannabis-related health issues, focusing on cannabis withdrawal syndrome and cannabis use disorder.
What is the goal of the CAN-001 study?
The CAN-001 study aims to evaluate the safety and efficacy of the investigational product PP-01 in alleviating cannabis withdrawal symptoms in patients with moderate to severe cannabis use disorder.
How does PP-01 work?
PP-01 combines nabilone and gabapentin, which work together to reduce withdrawal symptoms associated with cannabis use disorder.
What were the main findings from the study?
The study found that PP-01 significantly reduced cannabis withdrawal symptoms, improved sleep, and decreased cravings compared to a placebo.
What is the future direction for PleoPharma?
PleoPharma aims to bring PP-01 into Phase 3 studies with the goal of becoming the first FDA-approved treatment for cannabis withdrawal syndrome, addressing a critical healthcare need.
